drugset
drugset / Trial / NCT00515437

A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients

NCT00515437 ↗

Phase 2 Completed 54 enrolled Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

To determine safety, tolerability and preliminary efficacy of intraglandular injections of MYOBLOC for the treatment of sialorrhea in Parkinsons' Disease patients

Timeline

Start
2007-07
Primary completion
2008-06
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum Toxin Type B Unknown 1500 iu Other
Subject Botulinum Toxin Type B Unknown 2500 iu Other
Subject Botulinum Toxin Type B Unknown 3500 iu Other

Indications

No indication recorded.